Ovarian cancer is one of the deadliest gynecological malignancies and tends to be diagnosed at an advanced stage, with almost three-fourths of cases at the time of diagnosis being stage III-C or more. Its incidence is increasing globally. It is the third most common gynecological cancer in Indian women, with more than sixty thousand cases being diagnosed every year.

New therapeutic approaches aiming to prevent peritoneal recurrence are being evaluated. One of these approaches consists of associating a complete cytoreduction, removing the entirety of macroscopic lesions (including extensive peritonectomy and visceral resections if required so as to ensure no visible macroscopic disease at the end of surgery, contrary to the concept of debulking), with hyperthermic intraperitoneal chemotherapy (HIPEC), which is presumed to induce higher clearance of microscopic peritoneal lesions than with intravenous chemotherapy.